Prenuvo Body Composition

The Prenuvo Body Composition device, a Class II software medical device, is designed for non-invasive quantification of fat, muscle, and organs by processing DICOM-compliant magnetic-resonance image datasets from compatible MR systems. It has been found substantially equivalent to legally marketed devices, allowing its marketing under specific regulatory controls for individuals aged 18 and above.

The Prenuvo Body Composition device (K242825) has received a determination of substantial equivalence to legally marketed devices, thereby permitting its marketing. Classified as a Class II Magnetic Resonance Diagnostic Device, this software medical device is specifically designed for the non-invasive quantification of fat, muscle, and organs in individuals aged 18 years and above. It achieves this by utilizing DICOM-compliant magnetic-resonance image datasets obtained from compatible MR systems to display and analyze internal body structures, including the liver. Marketing of the Prenuvo Body Composition device is subject to adherence to a range of regulatory provisions. These include general controls such as annual registration, device listing, and good manufacturing practices, as well as specific Class II additional controls like the Quality System regulation, which covers design controls and corrective actions. Manufacturers are also mandated to comply with the Unique Device Identification System rule and report adverse events through the medical device reporting system, ensuring ongoing regulatory oversight.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. Given it's a software device using existing MR data, how does Prenuvo's algorithm improve upon or differ from existing methods of body composition analysis using MR imaging?; What are the specific performance metrics (e.g., accuracy, precision, reproducibility) of the Prenuvo Body Composition device for quantifying fat, muscle, and organ volumes in diverse patient populations?; Beyond quantification, does the device provide any insights into tissue characteristics or disease progression, especially regarding liver composition, which is specifically mentioned?; What are the compatibility requirements for MR systems and DICOM datasets to ensure optimal performance and reliable results from the Prenuvo software?; Are there any validated clinical applications or scenarios where the Prenuvo Body Composition device offers a significant advantage over other diagnostic tools for body composition assessment?